Ankylosing spondylitis: introductory comments on its diagnosis and treatment

M A Khan

Ankylosing spondylitis (AS) is a chronic systemic inflammatory rheumatic disorder of uncertain aetiology that primarily affects the axial skeleton (sacroiliac joints and spine). Sacroiliac joint involvement (sacroilitis) is its hallmark. The course of AS is highly variable and can be characterised by spontaneous remissions and exacerbation, particularly in early disease. The disease activity, however, generally persists for many decades, rarely entering a long term remission. The disease in some patients may be relatively mild or stay limited to the sacroiliac joints and the lumbar spine. Many patients may not seek medical help, which combined with the insidious nature of AS, may preclude an early diagnosis. There is currently no cure for AS, nor is there any medical intervention which can prevent or retard its progression.

DISEASE ONSET TO DIAGNOSIS: A BRIDGE TOO FAR

Only a doctor who is fully cognisant of the clinical nature of AS might consider the possibility of a spondyloarthropathy (SpA), much less AS, when presented with a young individual in their teens or early to mid-20s with chronic back pain. Yet, this is a typical initial presentation of AS. Unfortunately, the presence of inflammatory back pain during the clinically unrecognised “pre-spondylitic” phase, which on average might last 5–10 years or longer, is accompanied by progressive structural damage that may take place inconspicuously.

Diagnosis is often established when AS reaches the stage where structural damage has led to easily recognisable abnormal physical findings or readily apparent radiographic abnormalities of the sacroiliac joints and spine, or both.

Figure 1, which represents data collected by a 78 item professional survey of patients with AS conducted by the German AS society in 1996, illustrates well the protracted time delay between onset of AS and its diagnosis. A total of 1614 patients with AS responded to the questionnaire. The average age at onset of the disease was 25.7 years, and the average delay in diagnosis was 8.9 years. A significantly greater delay in diagnosis was 8.9 years; p<0.01). This discrepancy in disease progression may be related more to patients' clinical presentation and to clinicians' personal experience and intuition than precise diagnostic criteria. This clinical dilemma represents the wide chasm that exists between the onset of AS and its definite diagnosis and, subsequently, its appropriate treatment. Many researchers have attempted to bridge this gap by setting and refining guidelines for the diagnosis of AS. The modified New York diagnostic criteria commonly used today are readily applicable to patients showing clear radiological evidence of AS, but they are of limited use in the absence of defined radiological signs.

Many investigators have tried to set and refine guidelines for the diagnosis of AS. The modified New York diagnostic criteria commonly used today are readily applicable to patients showing clear radiological evidence of AS, but they are of limited use in the absence of defined radiological signs. For example, the definite diagnosis of AS cannot be made unless the patient shows unequivocal radiological evidence of grade II sacroilitis bilaterally, or grade III sacroilitis unilaterally. This misconception does not acknowledge juvenile patients or those in their late teens or early twenties with disease activity that has not yet progressed to the point where their sacroilitis is unequivocally detectable by x-ray examination. This is also true for those patients who may have an undifferentiated form of SpA that may progress over some years to meet eventually the modified New York criteria established for AS. Thus, the diagnosis and treatment of AS and related SpA in the early stages may often be related more to patients' clinical presentation and to clinicians' personal experience and intuition than precise diagnostic criteria. This clinical dilemma represents the wide chasm that exists between the onset of AS and its definite diagnosis and, subsequently, its appropriate treatment. Many researchers have attempted to bridge this gap by setting and refining guidelines for the diagnosis of AS.

Figure 1 Cumulative distribution of the age of disease onset (occurrence of the first spondylitic symptoms) and of the age at diagnosis for 920 male and 476 female patients with ankylosing spondylitis. Reproduced with permission from the authors and Current Opinion in Rheumatology from reference 5. Copyright © 2000 by Lippincott Williams & Wilkins.

Functional disability, which contribute to substantial socioeconomic loss and reduced quality of life.

Abbreviations: AS, ankylosing spondylitis; DMARDs, disease modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; TNFα, tumour necrosis factor α.
chiasm by establishing criteria for the early diagnosis of AS\(^1\)\(^4\)\(^14\); however, none of these criteria have been universally accepted. Thus, at present, doctors cannot look to established criteria for assistance in detecting early or atypical AS.

Early diagnosis of AS is highly desirable\(^6\) because (a) it enables the institution of treatment before permanent limitation of spinal mobility and spinal deformity have set in, and (b) it provides the clinician with the opportunity to monitor trends in spinal pathology that might result in abnormal posture. However, considerable progress is needed to improve the chances of a very early diagnosis of AS. Firstly, a global consensus needs to be reached on criteria for diagnosis and staging of AS—the aspects of clinical management that are fundamental to designing effective treatment strategies. Also, current diagnostic and classification systems for AS do not reflect the broad range of clinical and radiological presentations of the disease.\(^15\)\(^16\) This limits the ability of clinicians to diagnose patients with AS at an early stage and provide proper management.

These needs were recently acknowledged in a questionnaire based survey conducted by the experts participating in the Ankylosing Spondylitis Workshop held in Berlin, Germany, in January 2002, and resulted in a proposal for staging of patients with AS that is presented in this supplement. (see p iii\(^19\)) These offerings are an excellent starting point for establishing basic understandings among investigators and clinicians for the evaluation of treatment outcomes.

At present, a wide assortment of methods for assessment of AS has been suggested,\(^7\) but no particular method has been accepted universally, and no guidelines for the use of assessment measures have been established. Disease outcome depends on the speed of spinal ankylosis.\(^1\) There are many indicators for a severe disease outcome in patients with AS, such as onset at 16 years of age or younger, severe pain, grade IV radiographic spinal structural damage, limited spinal mobility, significant functional impairment, a need for regular pharmacological intervention, the lack of efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs), a requirement for corticosteroid or sulfasalazine treatment, ocular involvement, hip or knee involvement, and a requirement for surgery.\(^7\) Recently, the Assessments in Ankylosing Spondylitis Working Group defined a core set of domains for the evaluation of AS in the setting of disease controlling anti-rheumatic treatment and symptom modifying anti-rheumatic drug treatment in conjunction with physical therapy, and also for clinical record keeping.\(^8\)\(^9\) Which instruments most appropriately assess these domains—for example, the Bath Ankylosing Spondylitis Functional Index (BASFI) or the Dougados Functional Index (DFI) for function, and the visual analogue scale or the Bath AS Disease Activity Index (BASDAI) for pain, have yet to be determined. Moreover, application of the selected instrument in the assessment of treatment outcome, and the definition of treatment efficacy, are other unresolved issues.

**TREATMENT: IS IT TIME FOR A CHANGE IN PARADIGMS?**

Perhaps the most disheartening inadequacy in the care of patients with AS is the lack of therapeutic options which significantly impact and slow or halt disease progression. Unarguably, the use of NSAIDs rapidly relieves inflammatory back pain in patients with AS,\(^2\)\(^3\)\(^25\)\(^27\)\(^30\) earning these agents the status as the “gold standard” for drug treatment in AS.\(^9\) In fact, a dramatic response to NSAID treatment generally confirms the diagnosis of AS in a patient with a high index of clinical suspicion of the disease.\(^7\) However, patients experience clinical benefit only when they are regularly taking NSAIDs preferably in full anti-inflammatory dose.

The clinical benefit of these agents does not continue once these drugs are stopped. Furthermore, in many cases, NSAID use is limited by gastrointestinal side effects, with minimal clinical benefit from NSAIDs as the disease progresses. The inflammatory and erosive effects of AS result from the cytotoxic effects of TNFα on the gastrointestinal mucosa and occurs in most patients treated with NSAIDs.\(^23\) Most gastrointestinal symptoms are mild, but serious symptoms can sometimes occur, such as gastrointestinal bleeding and perforation.\(^23\) The risk of such serious gastrointestinal side effects is reduced by the use of newer but more expensive NSAIDs that selectively inhibit cyclo-oxygenase-2 (COX-2).\(^27\)\(^28\) However, COX-2 inhibitors (the so-called “coxibs”) are not more efficacious than conventional NSAIDs, and are not associated with a significantly lower incidence of the more common, less serious gastrointestinal side effects, such as nausea, and dyspepsia that bother most patients.\(^23\)\(^27\)\(^28\)\(^31\)\(^32\) Thus, as effective as NSAIDs may be, their overall clinical benefits are relatively limited.

For patients with AS refractory to NSAID treatment, the employment of disease modifying antirheumatic drugs (DMARDs) has been the second line approach, despite the lack of solid evidence of their efficacy. For example, sulfasalazine treatment is often used, but it is only effective in reducing synovitis in patients with peripheral joint involvement and has no beneficial effect on axial disease.\(^10\)\(^11\)\(^12\) Methotrexate is not effective in patients with AS who are unresponsive to NSAIDs and sulfasalazine.\(^13\)\(^13\)\(^15\) The use of some of the other DMARDs has also not been proved to be effective in placebo controlled trials,\(^33\)\(^34\) and their use is based primarily on anecdotal reports of efficacy or uncontrolled data.\(^30\)\(^33\) Intrararticular injection of corticosteroids into the sacroiliac joint under image enhancement (for example, with computed tomography and magnetic resonance imaging) often provides symptomatic relief for a variable duration, sometimes up to 10 months.\(^35\)\(^36\)

There is a clear need for effective new drug treatments for AS because no currently available drug can retard the process of fibrous and bony ankylosis and alter the natural course of the disease. None of the previously mentioned treatment options affect the underlying pathogenic mechanisms of the disease.

**NEW DIRECTIONS FOR TREATMENT**

In recent years great strides have been made in understanding the pathogenesis of chronic inflammatory rheumatic diseases, including AS. This progress is due largely to advances in molecular biology and biotechnology that allow researchers to examine the molecular mechanisms of inflammatory processes. The pathogenesis of AS is likely to be multifactorial and include genetic, immunological, and environmental mechanisms that may act in concert or may be intertwined.\(^37\)\(^38\)

In the past few years, tumour necrosis factor alpha (TNFα) has been identified as a key regulatory cytokine in the inflammatory cascade and has been the focus of research in the pathogenesis and treatment of rheumatic and other inflammatory disease states.

TNFα is the key proinflammatory cytokine involved in the pathological inflammatory process of rheumatoid arthritis (RA)\(^39\)\(^40\) and Crohn’s disease,\(^39\) a condition strongly associated with AS in either its subclinical or clinical form.\(^41\) In RA, TNFα mediates inflammation, development of pannus, and joint destruction. Its effects on endothelial cells result in up regulation of adhesion molecules, which facilitates leucocyte trafficking (E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1) and stimulates angiogenesis mediated by vascular endothelial growth factor\(^42\); TNFα also stimulates inflammatory cells (up regulates proinflammatory cytokines including interleukin 1, interleukin 6, and granulocyte macrophage colony stimulating factor) and synovial fibroblasts (stimulates synthesis of metalloproteinases that mediate bone and cartilage destruction, and induces proliferation of fibroblasts).\(^43\) In patients with RA there is a correlation between serum TNFα levels and disease severity and joint pain.\(^44\)
In Crohn’s disease, TNFα up regulates cell surface adhesion molecules, platelet activating factor, and interleukin 8 in endothelial cells and stimulates local production of chemotactic substances, thus facilitating the recruitment of circulating inflammatory cells to sites of mucosal inflammation. As in RA, TNFα in Crohn’s disease induces the production of other proinflammatory cytokines. In both RA and Crohn’s disease, neutralisation of the biological effects of TNFα has proved to be effective in managing these two diseases.

Clinical trials with the two anti-TNFα agents currently in clinical use, infliximab (a monoclonal anti-TNFα antibody) and etanercept (a soluble TNFα receptor fusion protein), have established their efficacy in reducing the signs and symptoms of RA. Perhaps the most exciting finding of these studies is radiographic evidence that pharmacologically blocking the action of TNFα is an effective mechanism for halting or retarding the progression of joint damage in RA. Infliximab and etanercept have recently become available for clinical use in the treatment of RA. Infliximab, in combination with methotrexate, is approved for reducing signs and symptoms, improving physical function, and inhibiting the progression of structural damage in patients with moderately to severely active RA who have had an inadequate response to methotrexate. Infliximab is also approved for the treatment of moderately to severely active Crohn’s disease inadequately responsive to conventional treatment. Etanercept is approved for the treatment of moderately to severely active RA in patients who have inadequate responses to one or more DMARD, or in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Several lines of evidence suggest a role of TNFα in the pathogenesis of AS. Firstly, the overexpression of TNFα has been documented in sacroiliac joints of patients with AS. Secondly, increased levels of TNFα have been detected in synovial fluid and synovial tissue from patients with psoriatic arthritis, another SpA. Thirdly, in vitro studies have demonstrated high concentrations of TNFα in gut mucosa biopsy samples taken from patients with Crohn’s disease, an inflammatory bowel disease strongly associated with AS. Finally, studies have shown abnormalities in the helper T cell subtype 1 (Th1) cytokine profile in patients with AS and related SpAs and in gut mucosal lymphocytes from patients with SpA. The latter finding links the gut immune system abnormalities to the pathogenesis of SpAs.

The hypothesis that TNFα has an important role in the pathogenesis of AS and related SpAs has been validated by the observed ability of anti-TNFα therapy (infliximab) to reverse Th1 cytokine abnormalities. Reduction in the thickness of the synovial layer has been seen in patients with SpA who are receiving anti-TNFα therapy, together with down regulation of endothelial adhesion molecules and reduction of inflammatory infiltrates in the synovial sublining area. Randomised, double blind, placebo controlled clinical trials have demonstrated the significant efficacy of infliximab and etanercept in reducing disease activity in patients with AS. Controlled studies have also shown their efficacy in psoriatic arthritis and other forms of SpAs. However, it is yet to be determined whether the immunomodulatory effects of anti-TNFα therapy that have thus far been observed will alter radiographic disease progression. There are also some new treatments under study, including pamidronate and thalidomide.

The emergence of data on the pathogenesis of these diseases and the molecular mechanism of the inflammatory process, as well as the development of new treatments that redress underlying pathogenic abnormalities, appear to be occurring in tandem. The workshop on the new treatment strategies was a timely event that provides a solid foundation to enable dramatic improvement in the management of patients with AS and related SpAs in the near future. For the first time there is a real possibility of controlling and modifying the course of these diseases for the betterment of the patients.

This review on the therapeutic advances in the management of AS does not cover surgical advances, such as cervical spinal fracture management with halo and vest. Figure 2 highlights these advances, showing a picture of the author who has had AS for the past 46 years.

Author’s affiliations
MA Khan, Case Western Reserve University, Cleveland, Ohio, USA
Correspondence to: Dr MA Khan, Case Western Reserve University, University School of Medicine, Division of Rheumatology, 2500 MetroHealth Drive, Cleveland, Ohio 44145, USA; makh@po.cwru.edu

REFERENCES


